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                  INTRODUCTION      
 INTRODUCTION 
    The thyroid gland is one of the most responsive organs in the body and 
is a large store of hormones. The gland responds to many stimuli and is in a 
constant state of adaptation. Thyroid hormones regulate the body's metabolism 
too. They have a bearing on the heart rate, cholesterol level, body weight, 
energy level, muscle strength, skin condition, menstrual regularity, memory 
function and many other conditions [1]. Diseases of thyroid gland especially 
mass lesions are easily accessible and amenable to surgical treatment and cure. 
              Thyroid malignancies represent the most common malignancies of the 
endocrine system. With environmental and genetic factors playing a role, there 
is an increase in incidence of these malignancies. Due to the dependence of 
thyroid on environmental iodine, it is particularly vulnerable to the genotoxic 
effects (DNA damage) of radioactive iodine and to the non genotoxic effects 
(TSH stimulation) resulting from iodine deficiency. The role of iodine is 
mediated through the growth stimulatory effects of high TSH levels [2].   
              With the use of improved and sophisticated diagnostic tools like guided 
Fine needle aspiration, PET scan etc., the incidence of detecting early thyroid 
neoplasms are on the rise, which pose challenge to the surgeons and to the 
pathologists. 
               The challenges for prognostication of these tumors are confounded as 
these neoplasms behave in an indolent fashion in many and aggressive in a few. 
Specific clinical and pathologic criteria are utilized to predict the biological 
behaviour of tumors as an achievement in modern medicine.  Staging criteria 
are used to evaluate the tumor not only for predicting prognosis of these tumors, 
but also to select appropriate therapy. The current staging parameters do not 
help in predicting patients who are likely to have a relapse. Hence a lot of 
molecules are being studied which would not only help to predict the biological 
behaviour, but also to plan scientific basis for therapy. One such molecule of 
interest is CD15. 
             CD15 (Leu M1, Cluster differentiation antigen 15) a blood group 
antigen, is a complex cluster of cell surface glycoproteins and glycolipids 
having a common terminal pentasaccaride known as Lewis X (Le x) antigen. 
Lewis X is a fucosylated derivative of N-acetyl lactosamine, a cell surface 
glycoprotein [3].  
               Synthesis of blood group antigens in the thyroid tissue is considered as 
‘oncofetal’, as they are not detected in the normal adult organ. Carcinomas of 
the thyroid gland show a significant increase in expression of these antigens 
possibly secondary to oncogenic transformation and subsequent increased 
production of  Lewis X molecules (Lacto-N-fucopentaose III ceramide), a 
component of the CD15 complex [4].  
                 Recent studies have shown the utility of CD15 as a prognostic marker. 
There are no studies from India which have looked into the expression of this 
molecule in thyroid neoplasms. This study therefore attempts to identify the 























AIMS AND OBJECTIVES 
 AIMS AND OBJECTIVES 
The aims of this study are 
1. To study the incidence of Immunohistochemical expression of CD-15 
in various   thyroid neoplasms 
2. To correlate the expression of CD15 with clinical presentation and 



















              
REVIEW OF 
LITERATURE 
 REVIEW OF LITERATURE 
               The thyroid gland develops from two lateral anlages and a median 
anlage. The medial anlage develops from the base of tongue, in the foramen 
cecum and becomes bilobed forming the greater portion of the thyroid gland 
and gives rise to the follicular epithelial cells. The follicular cells utilize iodine 
to form thyroxine and triiodothyronine. The lateral anlage develops as 
ultimobranchial bodies from the endoderm of fourth and fifth branchial pouches 
[4]. The ultimobranchial body fuses with the median anlage giving rise to the 
parafollicular C cells which secretes calcitonin.  
                Thyroid neoplasms account for approximately 1% of all cancer cases 
in the developed countries [1]. It affects all age groups although they are rare in 
children. The incidence increases throughout life. A female preponderance has 
been noted among patients in early and mid adult life, perhaps related to the 
expression of estrogen receptors on the tumor cells [5]. In contrast, neoplasms in 
childhood and late adult life are equally distributed with no sex predilection. It 
has been shown that thyroid nodules in older males harbor malignancy more 
commonly than in females with similar lesions. 
              Thyroid cancer is the only malignancy with age as one of the major 
prognostic indicator in the majority of staging systems. The mortality rate with 
thyroid cancer climbs gradually starting at age 40–45. With the same degree of 
cancer involvement, patients aged less than 45 have a distinctly different 
 prognosis than those aged more than 45 years. The reason for the distinctly 
different prognosis based on age is not entirely clear. The fact that the 
relationship exists suggests that there is something intrinsic to either the cancer 
or the treatment that is age dependent [6]. The association between advanced age 
and poor prognosis with thyroid cancer was hypothesized to a decline in 
immune system with age and a general increase in mortality from all causes 
with age [6]. 
               The incidence of thyroid neoplasms depends on the degree of iodine 
deficiency in the area. The ratio of papillary carcinoma to follicular carcinoma 
is higher in areas not endemic for iodine deficiency. Anaplastic carcinoma and 
follicular carcinoma are more often seen in iodine deficiency areas. Radiation is 
more closely associated with the development of papillary carcinoma than 
follicular neoplasms by causing double stand breaks in DNA, a precursor for 
RET and TRK rearrangements [7]. 
               A Chennai population based carcinoma registry released in 1984 
showed that thyroid neoplasms constituted for about 1% and 2% of all incident 
cancers among males and females respectively. Cumulative lifetime risk of 
thyroid cancer in Chennai was one in 970 for males and one in 565 for females 
[8]. A high dietary intake of iodine was proposed as a risk factor for the 
development of papillary carcinoma [9].  
                Table 1 gives a comparison of incidences of major types of malignant 
thyroid tumors between the reported world literature and that observed by Rosai 
J et al, Department of Pathology, SGPGIMS, Lucknow, India [10]. 
TABLE I: 





Papillary Carcinoma 60-80% 64 % 
Follicular Carcinoma 5-25 % 20% 
Medullary Carcinoma 5-10 % 7% 
Poorly differentiated (Insular) 
Carcinoma 
1-10 % 5% 
Undifferentiated (Anaplastic) 
Carcinoma 
4-10 % 4% 
 
               Primary epithelial neoplasms of thyroid originate from follicular 
epithelial cells. Follicular cell derived tumors include follicular adenoma, 
follicular carcinoma, papillary carcinoma and its variants, poorly differentiated 
carcinoma and anaplastic carcinoma.  Medullary carcinoma is a C- cell derived 
neoplasm comprising less than 10% of all malignant thyroid tumors [4]. Non 
epithelial tumors are very rare which include lymphoid malignancies and 
mesenchymal tumors. Metastatic tumors are very rarely encountered in the 
thyroid [11].  
                Among epithelial tumors, carcinomas of follicular origin outnumber 
those of C- cell origin [4]. Tumors arising from follicular epithelial cells exhibit 
a wide range of biologic behaviour. Papillary carcinoma is the commonest of all 
thyroid neoplasms. It behaves in an indolent fashion with a very low mortality. 
Medullary carcinoma and anaplastic carcinoma present as aggressive tumors 
leading to death within a year of diagnosis. Due to the heterogeneous behaviour 
of thyroid neoplasms, a need for correct histological diagnosis and classification 
is essential. 
CLASSIFICATION OF THYROID TUMORS (WHO 2004) [2]: 
         BENIGN           
                                   - Follicular adenoma 
         MALIGNANT 
                                  - Papillary carcinoma  
                                  - Follicular carcinoma  
                                  - Medullary carcinoma                                                                               
                                  - Poorly differentiated carcinoma (Anaplastic) 
                                  - Undifferentiated carcinoma (Insular) 
                                  - Mucinous carcinoma 
                                  - Muco- epidermoid carcinoma 
                                  -Squamous cell carcinoma 
                                  -Others 
 FOLLICULAR ADENOMA: 
                Follicular adenoma is a benign tumor showing a uniform pattern 
throughout and is enveloped by a thick fibrous capsule. Morphologically, it is 
composed of closely packed follicles, trabeculae or solid sheets of cuboidal or 
low columnar cells with pale or darkly stained nuclei and inconspicuous 
nucleoli. Prominent hyalinization and vasculature can be seen [9].   
                 Rare variants include atypical follicular adenoma, hyalinizing 
trabecular adenoma and Signet- ring cell follicular adenoma. Atypical follicular 
adenoma shows increased cellularity, mitoses, spontaneous necrosis or 
infarction and lack invasive growth [4, 9]. Hyalinizing trabecular adenoma is 
characterized by arrangement of the elongated tumor cells in a wavy trabecular 
pattern around capillaries in a background of lumpy hyaline material and 
calcified extracellular matrix. Nuclear grooves, pseudoinclusions and peri 
nuclear haloes are prominent [4]. Signet- ring cell follicular adenoma shows a 
predominance of signet ring cells with discrete cytoplasmic vacuoles, 
intermixed with groups of follicular cells of normal cytologic features [4]. 
                Hurthle cell adenomas are considered a subtype of follicular adenoma. 
They are bright brown macroscopically. The neoplasm is characterized by the 
presence of Hurthle cells arranged in follicular and / or trabecular pattern with 
partial or complete encapsulation. Morphologically, the Hurthle cells are large 
with voluminous eosinophilic cytoplasm and a round nucleus [11]. The granular 
 appearance of the cytoplasm is due to the accumulation of abundant 
mitochondria. These cells were first described by Askanazy in 1898 in Graves-
Basedow disease. It has a tendency for spontaneous infarction [11].  
PAPILLARY CARCINOMA: 
              Papillary carcinoma is the most common of all primary thyroid 
malignancies, accounting for about 70- 85% of cases [1]. It can affect any age 
and has a female preponderance. Papillary carcinoma is characterized by 
intrathyroidal invasion resulting in multifocal disease and metastasizes to 
regional lymph nodes. Extra thyroidal extension can occur and is defined 
grossly by Woolner et al as ‘extension of the tumor well beyond the capsule of 
the thyroid gland to involve such structures as the larynx, trachea or esophagus’ 
[12]. Extra thyroidal extension was defined microscopically by Carcangiu et al in 
their series as tumor ‘intimately admixed with the soft tissues, including skeletal 
muscle’ of the neck [13]. 
                Microscopically, classic type is characterized by formation of 
complex arborizing papillae with a central fibro vascular core. The papillae are 
covered by one or more layers of cells with crowded oval nuclei. The nuclei are 
enlarged and exhibit margination of chromatin, overlapping, with nuclear 
grooving and intra nuclear cytoplasmic pseudo inclusions [1, 4]. However, 
papillary thyroid carcinoma can exhibit a pure follicular pattern or mixed 
papillary and follicular pattern. Psammoma bodies, the lamellated concretions 
 formed by deposition of calcium upon the dying cells of the papillae are 
virtually pathognomonic of papillary carcinoma [11]. 
              The relation between papillary carcinoma and chronic lymphocytic 
thyroiditis is controversial [14, 15]. Reports by Livolsi suggested that the 
lymphocytic infiltration of the surrounding thyroid tissue is induced through 
autoimmune mechanisms triggered during the development of papillary 
carcinoma [14]. Singh et al found an increased prevalence of Hashimoto 
thyroiditis in patients with papillary thyroid carcinoma. The presence of 
coexistent Hashimoto thyroiditis did not affect the diagnostic evaluation or 
management of papillary thyroid cancers. They further hypothesized that the 
survival may be superior in patients who have papillary thyroid cancers with 
coexistent Hashimoto thyroiditis [15]. 
VARIANTS OF PAPILLARY CARCINOMA: 
              Several morphological variants of papillary carcinoma have been 
recognized based on the architecture, growth pattern, cellular morphology and 
stromal features. The recognition of these subtypes becomes important as some 
of them are more aggressive in their biologic and clinical behaviour irrespective 
of their bland appearance. 
 
 
             I. Papillary microcarcinoma: 
              Papillary carcinomas measuring 1 cm or less in diameter are termed as 
papillary micro carcinomas. The tumor is most often unencapsulated and 
sclerosing [2]. A familial occurrence has been reported by Lupoli et al in a subset 
of patients with papillary micro carcinoma [16]. It is frequently detected in 
autopsy or in thyroidectomy specimens for other indications and is associated 
with an excellent prognosis despite occasional regional lymph node metastasis. 
           II. Follicular variant:  
              Under the microscope, the neoplasm is composed of small to medium 
sized, irregularly shaped follicles with virtually no papillary structures. Stromal 
sclerosis and psammoma bodies can be present. Characteristic nuclear features 
of papillary carcinoma are evident [17]. Distant metastasis and vascular invasion 
are common. Nodal metastasis and extra thyroidal extension are rare. Some of 
these tumors exhibit encapsulation with an exceptionally good prognosis (so 
called Lindsay tumor) [18]. The behaviour is similar to that of conventional 
papillary carcinoma. 
           III. Tall cell variant: 
               This is a rare variant and consists predominantly of tumor cells whose 
heights are at least three times their widths. Tall cells must be seen in 50% or 
more of the tumor areas to make a diagnosis of tall cell variant of papillary 
 thyroid carcinoma. Necrosis, mitotic activity and extra thyroidal extension are 
common. These tumors occur in older patients, often males, with a more 
aggressive clinical behaviour [17]. Tall cell variant of papillary carcinoma 
frequently show strong immunostaining for CD15 expression. 
           IV. Oncocytic variant: 
                Oncocytic papillary carcinomas are characterized grossly, by a 
distinct mahogany appearance. The complex branching papillae have a thin 
fibro vascular stromal core, covered by a single layer of polygonal oncocytic 
cells with abundant granular eosinophilic cytoplasm [2, 17].  
          V. Warthin tumor like variant:  
              This variant has a brisk lymphoplasmacytic infiltrate in the papillary 
stalks with circumscription and central cyst formation. Papillae and follicles 
were lined by oncocytic cells with the typical nuclear features of usual papillary 
carcinoma. Psammoma bodies can be seen. It is frequently associated with 
Hashimoto thyroiditis [19, 20]. The immuno profile of the lymphoid cells is no 
different from chronic lymphocytic thyroiditis. 
          VI. Cribriform morular variant: 
              Focal papillary architecture, cribriform features, solid and spindle cell 
areas interspersed with squamoid morules, characterize this variant of papillary 
carcinoma. The nuclei frequently harbor eosinophilic, homogenous cytoplasmic 
 inclusions. It typically occurs in patients with familial adenomatous polyposis 
or Gardner syndrome [4]. In this setting, the tumor is often multifocal and occurs 
in young women [17]. 
           VII. Clear cell variant: 
               Tumor cells have abundant clear or vacuolated cytoplasm. 
Cytoplasmic clearing is usually due to accumulation of glycogen. The nuclear 
features are otherwise typical of papillary carcinoma. Recognition of this variant 
in metastatic sites may be problematic [17, 18]. 
           VIII. Diffuse sclerosing variant: 
               This is an unusual variant of papillary carcinoma seen more frequently 
in children and is associated with a poor prognosis. Diffuse involvement of both 
the lobes is characteristic. The microscopic hallmark is the presence of 
widespread intra thyroid lymphatic permeation by numerous neoplastic micro 
papillae and a dense sclerotic stroma [17]. 
FOLLICULAR CARCINOMA: 
               It comprises 5-15% of all thyroid malignancies [1]. Follicular 
carcinoma is more common in women of older age group and in the iodine 
deficient areas [4]. The tumor can be encapsulated or widely invasive. A true 
capsular and / or a vascular invasion in a follicular neoplasm [9, 11] is mandatory 
to diagnose follicular carcinoma. 
               Capsular invasion is defined by tumor penetration through the tumor 
capsule unassociated with the site of a previous fine needle aspiration biopsy[21]. 
               Vascular invasion is defined by the presence of intravascular tumor 
cells either covered with endothelium or associated with thrombus formation 
within or beyond the tumor capsule [9, 21]. 
               Angio-invasive tumors have a high chance to metastasize 
hematogenously to bone and lungs. Follicular carcinomas lack multifocality and 
do not invade lymphatics. The tumor grows as a combination of solid, 
trabecular and follicular growth patterns. The metastatic lesions from follicular 
carcinoma are histologically similar to the primary neoplasm in the thyroid [4]. It 
can also be deceptively bland and mimic normal thyroid tissue. 
               Tumors with limited focal capsular and / or vascular invasion that are 
apparent only on histological examination are termed as ‘Minimally invasive 
follicular carcinomas’ [2, 22]. ‘Follicular tumors of uncertain malignant potential’ 
are designated, if the presence or absence of invasion is not certain or 
unequivocal, [2]. 
MEDULLARY CARCINOMA: 
               Medullary carcinoma is a malignant tumor of the thyroid gland, with 
evidence of parafollicular C cell differentiation. It comprises about 10% of all 
malignant thyroid malignancies [4]. Calcitonin secretion is characteristic. It 
 occurs in the setting of several inherited cancer syndromes including multiple 
endocrine neoplasia (MEN) syndromes. Medullary carcinoma can exhibit 
trabecular, insular or sheet like growth patterns traversed by delicate fibro 
vascular septa. The cells are small with stippled chromatin. Amyloid deposits 
are seen separating the tumor cell nests. Tumor necrosis and mitotic figures are 
infrequent. Lymphatic invasion, extra thyroidal involvement by direct extension 
and intra glandular metastasis can be present [9, 11].  
POORLY DIFFERENTIATED CARCINOMA: 
               Poorly differentiated thyroid carcinoma or insular carcinoma 
represents a heterogeneous group of malignant neoplasms, with varied growth 
patterns and biological behaviour. It grows in the form of large solid nests, 
punctuated by variable number of small abortive follicles with a thin fibro 
vascular septa and retraction artifact around. The cells are small, uniform with 
hyper chromatic or vesicular nucleus and variable mitotic activity. Prominent 
vascularization, coagulative necrosis, infiltrative growth pattern and obvious 
vascular invasion are characteristic [2]. 
              Apart from tumor stage, tumor necrosis, mitotic count of more than 3 
per 10 high power fields and the age more than 45 years have been reported as 
being significantly associated with the aggressive biological behaviour of the 
disease [9, 17]. 
 ANAPLASTIC CARCINOMA: 
               Anaplastic carcinoma or undifferentiated thyroid carcinoma accounts 
for about 5 - 10% of thyroid malignancies. The tumor is usually seen in iodine 
deficient areas and in elderly patients with a rapidly enlarging mass [2]. 
Anaplastic carcinoma exhibits a wide spectrum of morphologic patterns and cell 
types, predominant being epithelioid cells, spindle cells and giant cells. Focal 
squamoid differentiation and osteoclast like giant cells can be evident. The 
tumor also shows frequent mitoses, extensive coagulative necrosis and marked 
degree of invasion into the surrounding soft tissues [2]. Prominent 
vascularization and vascular invasion are common with obliteration of the 
vascular lumina. Distant metastasis is frequent and behaves in an aggressive 
fashion. A pre-existing well differentiated thyroid neoplasm, more often 
follicular or papillary carcinoma is usually seen in many, if not in most of the 
undifferentiated carcinomas [11, 17, 22]. 
TNM CLASSIFICATION AND STAGING OF THYROID CARCINOMAS [2]: 
               A staging and grading system is a standard way for the cancer care 
team to summarize how large a cancer is and how far it has spread. The TNM 
system is endorsed by the International Union against Cancer (UICC) and the 
American Joint Commission on Cancer (AJCC) and is commonly used. 
 
 T- PRIMARY TUMOR 
TX       Primary cannot be assessed. 
T0        No evidence of primary tumor. 
T1       Tumor 2 cm or less in greatest dimension, limited to thyroid. 
T2       Tumor more than 2 cm but not more than 4 cm in greatest dimension,     
limited to thyroid. 
T3       Tumor more than 4 cm in greatest dimension, limited to thyroid or any 
tumor with minimal extra thyroidal extension (e.g. extension to sternothyroid 
muscle or perithyroid soft tissues) limited to the thyroid. 
T4a     Tumor extends beyond the thyroid capsule and invades any of the 
following: subcutaneous soft tissues, larynx, trachea, esophagus, recurrent 
laryngeal nerve* 
T4b   Tumor invades prevertebral fascia, mediastinal vessels, or encases carotid 
artery* 
 
T4a*    (Anaplastic carcinoma only) Tumor (any size), limited to the thyroid** 
T4b*  (Anaplastic carcinoma only) Tumor (any size), extends beyond the 
thyroid capsule***. 
 Notes: Multifocal tumours of all histological types should be designated (m). 
* All Anaplastic/undifferentiated thyroid carcinomas are considered T4. 
** Intrathyroidal anaplastic carcinoma – considered surgically resectable.     
*** Extra thyroidal anaplastic carcinoma – considered surgically unresectable. 
N-REGIONAL LYMPH NODES 
NX      Regional lymph nodes cannot be assessed. 
N0.      No regional lymph node metastasis. 
N1       Regional lymph node metastasis. 
N1a     Metastasis to Level VI (pretracheal, paratracheal and prelaryngeal / 
Delphian) lymph nodes. 
N1b    Metastasis to unilateral, bilateral or contra lateral cervical or superior 
mediastinal lymph nodes. 
M – DISTANT METASTASIS 
MX    Distant metastasis cannot be assessed. 
M0    No distant metastasis 
M1    Distant metastasis 
STAGE GROUPING: 
               Separate stage groupings are recommended for papillary and follicular, 
medullary and anaplastic/ undifferentiated carcinomas. Unlike most other 
 cancers, thyroid carcinomas are grouped into stages in a way that considers both 
the subtype of the neoplasm and the patient’s age [2]. 
                             Papillary or Follicular under 45 years 
Stage I                   Any T            Any N              M0 
Stage II                 Any T             Any N             M1 
       Papillary or Follicular, 45 years and older and Medullary of any age 
Stage I                     T1                   N0                 M0 
Stage II                   T2                    N0                 M0 
Stage III                  T3                    N0                 M0 
                           T1, T2, T3           N1a                M0 
Stage IVA          T1, T2, T3           N1b                M0 
                                 T4a              N0, N1             M0 
Stage IVB                 T4b           Any N                M0 
Stage IVC               Any T         Any N                M1                                  
                  Anaplastic/ Undifferentiated (all are considered stage IV) 
Stage IVA                T4a           Any N                M0 
Stage IVB                T4b           Any N                M0                                        




              Tumor grading in thyroid malignancies is of little significance as more 
than 95% of cases are well differentiated using standard grading criteria [2]. 
However tumor necrosis, vascular invasion, increased mitoses and marked 
nuclear atypia have been associated with a less favorable prognosis in papillary 
carcinoma [17]. Certain variants such as tall cell variant and diffuse sclerosing 
variants are also associated with an aggressive clinical behaviour [9, 11]. 
Biological behaviour of follicular carcinoma can be predicted based on tumor 
size, local extension and presence of distant metastasis [18]. Medullary 
carcinoma with necrosis, squamous metaplasia and distant metastasis are 
associated with poor survival [23]. 
CD15 (Leu M1): A GENERAL REVIEW 
              Leu-M1, a blood group antigen was first reported as reactive with the 
membrane-related trisaccharide fucosyl-N-acetyl lactosamine on myelo-
monocytic cells, where the epitope was known as X-Hapten or Lewis-X. The 
gene is located on chromosome 11 in the region q12 [3]. 
               CD15 (Cluster differentiation antigen) is a complex cluster of cell 
surface glycoproteins and glycolipids having a common terminal pentasaccaride 
known as Lewis X (Le x) antigen. It is implicated in cell to cell adhesion 
mediated by carbohydrate-specific ligands.  The core proteins and lipids differ 
in the different cell types, as there is marked variability in the binding of the 
 antibodies within and among them [24]. CD15 plays a role in increasing 
neutrophils adhesion, mediating phagocytosis, bactericidal activity by 
stimulation of degranulation, respiratory bursts and chemo taxis [25]. 
               CD15 is also a haemopoietic differentiation antigen expressed on most 
terminally differentiated myeloid cells and Langerhans’ cells [26]. It is also found 
in epithelial cells such as Breast (secretory epithelium), Kidney (proximal 
tubular cells), Lung and Intestinal tract (including Paneth cells). In the Brain, 
CD15 is constantly expressed in astrocytes and variably in Oligodendrocytes 
and Neurons. Complex glycoproteins containing fucose (such as Leu-M1) have 
been identified in epithelial cells lining the intestinal walls in early 
embryogenesis [27]. 
               The CD15 antigen is present in more than 95% of the mature 
peripheral blood eosinophils and neutrophils and is also present in low density 
on circulating monocytes but not on basophils or lymphocytes [26]. In lymphoid 
tissue, CD15 reacts with Reed-Sternberg cells of Hodgkin's disease and with 
granulocytes [27]; however, CD15 reacts with a few tissue macrophages and does 
not react with dendritic cells. Antibodies to Leu-M1, like most CD 15 
antibodies, developed are immunoglobulin M antibodies that recognize a 
specific sugar sequence in the complex glycolipids and glycoproteins such as 
lacto-N-fucopentaose III ceramide in the cells [25]. 
                CD15 is expressed in varying proportions of epithelial derived tumors 
such as adenocarcinoma, renal cell carcinoma, and embryonal carcinoma and 
also occasionally in large cell lymphomas of both B and T cell phenotypes. 
These antigens are useful in the classification of leukemia, in distinguishing 
Hodgkin disease from non- Hodgkin’s lymphoma, in further sub typing of 
Hodgkin lymphoma, and in differentiating metastatic adenocarcinoma from 
malignant mesothelioma. CD 15 a marker for murine pluripotent stem cells, in 
which it plays an important role in adhesion and migration of the cells in the 
preimplantation embryo [27]. 
               Activation of CD15 results in cell activation of monocytes [28]. Sui et al 
suggested that E-selectin interaction with sialyl- CD15 may predominately 
mediate initial monocyte tethering, while concomitant or subsequent 
engagement of the nonsialylated form then mediates cell activation [28]. A role in 
cell-cell recognition during neuronal development is suggested by the 
observation that monoclonal antibodies against Lewis X inhibit the adhesion of 
cerebellar granule cells to astrocytes and block neurite outgrowth. CD15 
containing molecules are also secreted in the neural tissues and have been 
shown to bind with Wnt-1, suggesting that CD15 may bind and present growth 
factors important for the proliferation and self-renewal of neural progenitors 
during embryonal life [25].  
 
 CD15 EXPRESSION IN THYROID CARCINOMAS: 
               For most thyroid tumors, a diagnosis of thyroid malignancy can be 
reached by morphological assessment alone. As of now in India, the diagnosis 
of papillary thyroid carcinoma is based on nuclear features. However, these 
features may be seen in some benign lesions too. Invasion of the capsule and/ or 
vascular channels represent diagnostic criteria for follicular carcinoma. Many a 
times, it is difficult to confirm by morphology alone [2]. At the same time, in 
tumors exhibiting unusual patterns or for confirmation of a diagnosis and to 
establish the prognosis, Immunohistochemical study becomes essential. 
               Blood group antigen (Lewis X) expression has been described in fetal 
tissues and tumorous tissues. They are present only in the initial embryologic 
developmental stages and are absent when organ maturation is completed. 
Synthesis of blood group antigen in the thyroid tissue is considered as 
‘oncofetal’ as they are not detected in the normal adult organ. Carcinomas of the 
thyroid gland show a significant increase in expression of this antigen possibly 
secondary to oncogenic transformation and subsequent increased production of  
Lacto-N-fucopentaose III ceramide [24]. However, no correlation exists between 
antigen expression and degree of differentiation of the tumor. Anaplastic 
carcinomas were found to be negative for CD15 indicating the loss of these 
epitopes upon high grade malignant transformation [29]. 
                The degree of epithelial Leu-M1 expression was significantly related 
to the biological behaviour of papillary and medullary thyroid neoplasms. 
Mortality was found to be 17 times more frequent among papillary tumors with 
marked positivity (>15%). Among medullary carcinomas, local recurrences 
occurred 2.9 times and death resulting from tumor occurred 4.3 times more 
frequently for intensely stained neoplasms as compared to slightly 
immunoreactive or unstained neoplasms [30].  
               It is established by Ito et al that, blood group related antigens like 
CD15 are expressed exclusively in papillary carcinoma of the thyroid gland [31]. 
Many studies have evaluated CD 15 expression in medullary thyroid 
carcinomas and follicular neoplasms as well and it was observed that its 
expression is more likely to be found in tumors with metastases than in those 
without metastases [32]. Van Hoeven et al illustrated that papillary thyroid 
carcinomas were the most immunoreactive for the blood group antigens and its 
expression in medullary carcinoma may be related to a biologically aggressive 
behaviour [33]. 
               Larena et al reported a significant and progressive increase in 
expression of blood group antigens in carcinomas of the thyroid gland of higher 
grade and stage with no expression in normal thyroid tissue [34]. A significant 
higher level of recurrence and metastasizing capacity were observed by them in 
the neoplasms with significant blood group antigen expression [34]. 
                A study reported by Mai et al states that CD 15 expression was 
specific although not sensitive to diagnose papillary thyroid carcinoma. This 
study revealed that CD 15 immunostaining in combination with CK 19 or 
HBME can achieve a sensitivity of 95% and specificity of 90% for the 
diagnosis of papillary carcinoma and hence will clarify the histological type in 
problem cases [35]. 
              CD15 immuno reactivity may be helpful in the histological differential 
diagnosis between benign lesions and well differentiated thyroid neoplasms as 
well, and increased CD15 reactivity in malignant thyroid tumors reflects 
changes in thyroid follicular epithelial cell conjugates related to malignant 
transformation [36]. High grade expressions of these antigens were observed 
among the patients who presented with Masumane- Davidsohn phenomenon, 
where the tumor cells lack the expression of ABO blood group antigens. This 
was interpreted by Campora et al as a result of blockade in A and B antigen 
formation and the subsequent production of Leu antigens in the tumor cells [37]. 
               As overlapping morphological patterns observed in various benign and 
carcinomatous lesions can limit the evaluation, Van Hoeven et al identified that 
CD15 can be used as a less sensitive but more specific marker to classify such 
morphologically unequivocal lesions [33]. 
              Miettinen et al found a marked epithelial Leu M1 immunoreactivity in 
papillary thyroid carcinomas at an advanced stage of disease [38]. These findings 
 suggest that, CD15 positivity is associated with a poorer prognosis and provides 
significant prognostic information for patients with papillary carcinoma of the 
thyroid gland [38]. Schroder et al suggested that CD 15 positivity is associated 
with a poor prognosis.  The degree of epithelial Leu- M1 expression was 
significantly related to the clinical course of papillary neoplasms. A good 
correlation was found between Leu-M1 immunoreactivity in papillary 
carcinomas with advanced pathological stage and cancer related deaths [39]. 
               CD15 immunoreactivity may be helpful to assist differential diagnosis 
of thyroid carcinoma from benign thyroid diseases. Leu-M1 positive cases 
exhibited more advanced pathological stage, lymph node metastases and a 
greater incidence of tumor associated mortality than Leu-M1 negative cases [40]. 
Willgeroth et al found a poor post operative course of disease in patients with 
Leu-M1 positive tumor cells in comparison to Leu-M1 negative tumors [41]. 
               Studies by Ostrowski and Merino emphasized that CD15 expression 
can be used as an indicator of advanced stage of the disease. The study also 
revealed diffuse Leu-M1 staining in all cases of tall cell variant of papillary 
carcinoma and typically exhibited a strong cytoplasmic to membranous staining 
pattern[42]. Strong expression of CD 15 in the tall cell variant correlates well 
with the aggressive clinical behaviour of these tumors compared to usual 
papillary carcinomas [9, 11, 43]. 
                Neuhold et al found a significantly higher epithelial CD 15 positivity 
in the group with size greater than 4 cm and was also found exclusively in the 
presence of lymph node metastases [44]. No substantial difference in 
immunostaining was seen between primary thyroid neoplasms and metastatic or 
recurrent lesions. However, it was suggested that in patients particularly with 
tumor recurrences, CD 15 immunostaining may be of clinical relevance for the 
selection of patients in whom a more radical surgical approach would be 
justified. 
















   MATERIALS AND 
METHODS       
 MATERIALS AND METHODS 
              All those cases diagnosed as a thyroid neoplasm between the period of 
Jan 2006 to Sep 2009 in the Department of Pathology, PSG Institute of Medical 
Sciences and Research, Coimbatore were included in the study.  
              The clinical details of these cases were taken from the medical records 
department of PSG IMSR after obtaining permission from the authorities. Age, 
sex, clinical presentation, hormone status and follow up were obtained by 
analyzing the case records.               
              The slides of all the cases were screened and were analyzed for the 
following: the type of neoplasm, nuclear features, invasion into the capsule and 
vascular spaces, extra thyroidal extension, lymph node metastases, mitoses, 
necrosis and presence or absence of Amyloid. Paraffin blocks of those sections 
which had high tumor density were chosen for the study. Paraffin blocks of 
slides which showed tumor with large areas of hemorrhage, cystic change and 
necrosis were not considered for the study. The T and N status of the malignant 
neoplasms was also noted for staging. 
               4μ thick sections from the chosen paraffin blocks were made. They 
were mounted onto the glass slides and were stained with routine hematoxylin 
and eosin stain. These slides were reassessed for adequacy. Fresh sections from 
 the blocks were cut again at 5μ thickness and taken on to a Poly-L-Lysine 
coated slide. 
              Tissue blocks of normal kidney were taken from the nephrectomy 
specimens received. The blocks were then cut to 5μ thickness and taken on to a 
Poly-L-Lysine coated slide to serve as a positive control for CD15 [3]. 
              Immunohistochemistry for the detection of CD15 expression was done 
using the super sensitive polymer – HRP detection system along with 
appropriate control (normal kidney).  3, 3’diaminobenzidine tetra hydrochloride 
(DAB) was used as the chromogen. The procedure followed is described below. 
METHOD:  The supersensitive polymer – HRP detection system 
ANTIBODY: CD15 (Biogenex, clone BRA4F1) 
PRINCIPLE: Antigens in tissues and cells was detected by a two stage process: 
the binding of the primary antibody to specific epitopes and subsequent 
detection of this bound antibody by a colorimetric reaction using a substrate 
chromogen [45]. 
               The method is based on the utility of compact dextran polymer to 
which multiple molecules of the enzyme (Horse radish peroxidase) are attached 
to each linker secondary antibody (specific for the unconjugated primary 
antibody). A primary antibody (CD15) for the antigen to be localised is first 
employed. This is followed by the addition of dextran polymer with multiple 
 conjugated secondary antibodies. Multiple secondary antibodies react with 
different antigenic sites on the primary antibody, thereby increasing the signal 
amplification with the use of a suitable chromogen 3, 3’diaminobenzidine tetra 
hydrochloride (DAB) [24, 45]. 
 
                       Primary antibody                                Secondary antibody 
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 ANTIGEN RETRIEVAL: Various methods are used to expose the antigenic 
sites (epitopes) that may be unexposed (masked) during routine processing due 
to formation of cross linking by the action of formalin [45]. The methods to 
unmask the epitopes include digestion with a variety of proteolytic enzymes, 
microwave heating, and lastly exposure to the combined effects of heat and 
pressure in a stainless steel pressure cooker as is said to be more uniform. It can 
recover almost full antigenicity. In this study, antigen retrieval was carried out 
using pressure cooker for 10 min, using Citrate Buffer at a pH of 6.0. 
REAGENTS:  
1. Citrate buffer at pH of 6.0. It was prepared by dissolving Tri sodium citrate 
(2.94g) in 1000ml of distilled water and 5ml of 1 N Hcl.                        
2. 3% H2O2 in distilled water to block endogenous peroxidase activity. 
3. Phosphate buffered saline (PBS) with a molarity of 0.01M and the pH value 
of 7.6. It was prepared by dissolving the following substances in 1000 ml of 
distilled water. 
Na2HPO4 Dibasic sodium phosphate, anhydrate              17.5g 
KH2PO4 Monobasic potassium phosphate, anhydrous     2.5g  
NaCl Sodium chloride                                                      17.0g    
 4. Blocking reagent- contained casein in PBS with 15mM sodium azide. This 
was used to blocks non specific protein binding. 
5. Primary antibody against CD15 is a mouse monoclonal antibody supplied in 
liquid form. (Biogenex, clone BRA4F1). 
6. Poly HRP reagent- anti-mouse and anti-rabbit IgG complex linked to Horse 
radish peroxidase enzyme. 
7. DAB (3, 3’Diamino Benzidine tetra hydrochloride) - Chromogen. 
     It offers great sensitivity as an HRP calorimetric chromogen and provides 
insoluble permanent coarse brown precipitate. 
8. Harris hematoxylin as counter stain. 
9.  DPX (Distrene dibutyl phthalate Xylene) - Mountant. 
PROCEDURE:   
1. Sections were cut at 4μ thickness and taken on a egg albumin coated    
slide. 
2. Routine Hematoxylin and eosin stain was done and reassessed. 
3. Sections were cut at 5 micron thickness and taken on a Poly-L-Lysine 
coated    slide. 
 
   4. Immunohistochemical Stain with CD15 antigen was done as follows 
        a. Slides were dewaxed and dehydrated in graded alcohol. 
        b. Heat induced antigen retrieval in citrate buffer at pH 6.0 using pressure 
cooker for 10 minutes  
        c. Washed in PBS buffer at pH 7.6 for 5 minutes twice 
        d. Slides were immersed in 0.3% H2O2 solution for 20 minutes to block 
endogenous peroxidase activity. 
        e. Washed in PBS buffer thrice each 5 minutes 
        f. Slides incubated with blocking solution for 10 minutes to block non-
specific protein binding. 
        g. Washed in PBS buffer thrice. 
        h. Slides were incubated with CD 15 primary antibody for 1 Hr. 
        i. Enhancer was applied to the sections for 30 minutes to enhance the 
signal intensity. 
        j. Washed in PBS buffer thrice. 
        k. Slides were incubated with polymer Horse radish peroxidase reagent. 
        l. Washed in PBS buffer thrice. 
        m. Diamino Benzidine (DAB) is applied. 
         n. Washed in PBS buffer thrice. 
        o. Sections counter stained with Harris hematoxylin for 1 minute. 
        p. Washed in tap water. 
        q. Sections cleared in Xylene and mounted with DPX mountant.  
              Tumors cells were scored positive if there was Brown Cytoplasmic peri 
nuclear dot like staining or membranous accentuation in more than 10% of the 
neoplastic cells. Scoring is done in the well stained area with no interference by 
nonspecific staining background.  
Immunoreactivity is evaluated as follows: 
 (-)      absolutely no cells show immunostaining. 
(+/-)   <10% of neoplastic cells show weak or focal reactivity. 
(+)     10 – 50% of neoplastic cells show moderate to strong reactivity. 

















              The Department of Pathology, PSG Institute of Medical Sciences and 
Research has received 15739 biopsy specimens over a period of 3 years and 9 
months from 1st Jan 2006 to 30th Sep 2009, of which 266 were Thyroidectomy 
specimens. The total numbers of malignancies reported in our institute during 
this study period were 2953, out of which thyroid neoplasms were 64 with an 
overall incidence of 2.16 % of the total cancer cases ranging from 1.65% to 
2.72% during the study period.  
TABLE II:  Incidence of thyroid neoplasms during the study period. 
Year 
Total no of 
neoplasms diagnosed
No of Thyroid 
neoplasms 
Incidence of thyroid 
neoplasms 
2006 625 17 2.72% 
2007 819 19 2.32% 
2008 847 14 1.65% 
Sep 2009 662 14 2.11% 
Total 2953 64 2.16% 
 
               Based on the inclusion criteria, the number of cases in the study group 
was 50. Out of these 50 cases, 30 were papillary thyroid carcinoma, 17 were 
follicular neoplasms [follicular adenoma (12), minimally invasive follicular 
 carcinoma (2) and 1 each of  follicular neoplasm of uncertain malignant 
potential, microfollicular adenoma of signet ring cell type and Hurthle cell 
adenoma), two cases of medullary carcinoma and a single case of anaplastic 
carcinoma with coexisting follicular carcinoma.  Minimally invasive follicular 
carcinoma, follicular neoplasm of uncertain malignant potential, microfollicular 
adenoma of signet ring cell type, Hurthle cell adenoma and anaplastic 
carcinoma were placed under miscellaneous category. The breakup and 
incidence of various types of thyroid neoplasms during the study period is as 
shown in the table III. 
TABLE III: Distribution of thyroid neoplasms during the study period. 
Year 









2006 17 9 (53%) 4 (23.5%) 1 (5.9%) 3 (17.6%) 
2007 19 12 (63.2%) 5 (26.3%) 1 (5.3%) 1 (5.2%) 
2008 14 11 (78.6%) 2 (14.3%) 0 1 (7.1%) 
Sep 2009 14 9 (64.3%) 4 (28.5%) 0 1 (7.1%) 





 THYROID NEOPLASMS- AGE WISE DISTRIBUTION:                
                  The age group ranged from 20 to 70 years with a mean age of 45 
years. Papillary thyroid carcinoma was predominantly seen in the second and 
fourth decades.  Follicular neoplasms dominated in the third decade. Medullary 
carcinoma was seen in the third and sixth decades of life. A single case of 
anaplastic carcinoma in our study was in a 40 year old female, contrary to what 
is described in the literature (i.e., usually seen in the elderly). Table IV shows 
the age wise distribution of patients among various neoplasms of thyroid. 
TABLE IV: Distribution of various thyroid neoplasms age - wise 









20 - 30 11 2 0 0 
31 – 40 3 7 1 1 
41 – 50 9 5 0 0 
51 – 60 5 3 0 0 
61 – 70 2 0 1 0 
71 - 80 0 0 0 0 
TOTAL 30 17 2 1 
 
 
 THYROID NEOPLASMS- SEX WISE DISTRIBUTION:                
               Of the 50 cases, 13 were males and 37 were females giving rise to an 
M: F ratio of 1:2.8. Sex distribution among various neoplasms was also 
observed. Out of 30 cases of papillary carcinomas, 6 were in males against 24 
females with an M: F ratio of 1:4. Both the cases of medullary carcinoma 
occurred in males and that of the anaplastic carcinoma were in a female. Among 
follicular neoplasms, 12 cases were females and 5 were males which also 
showed a female predominance. Table V and chart I shows the sex distribution 
of thyroid neoplasms of various types, which clearly depicts female predilection 
of papillary and follicular thyroid carcinomas in our study group as comparable 
with the literature. 
CHART I: Distribution of thyroid neoplasms sex – wise: 
     
 





THYROID NEOPLASMS- HORMONE STATUS ANALYSIS:                
               Hormone status was obtained for these cases from the case records. 
Free T3 and T4 levels and TSH levels were taken and interpreted. Out of 50 
patients, 42 patients were in euthyroid state accounting for about 84% and three 
each in hypothyroid and hyperthyroid status. For two patients, hormone statuses 
were not available as shown in Table VI. Of the two cases of medullary 
carcinoma encountered in the study, serum calcitonin level was found to be 
elevated (2ng/ml) pre-operatively.  
TABLE VI: Hormone status analysis of thyroid neoplasms: 
Hormone status Euthyroid Hypothyroid Hyperthyroid Not available












Male 6 5 2 0 
Female 24 12 0 1 
 THYROID NEOPLASMS- GROSS PATTERN ANALYSIS:                
               Sizes of various thyroid neoplasms studied ranged from 0.4 cms to 
11.5 cms. Table VII shows the size wise distribution of cases among various 
types of thyroid neoplasms.  










<2cm 13 1 0 0 
2 – 4 cm 13 10 2 0 
>4 cm 3 6 0 1 
Not 
assessed 
1 0 0 0 
 
               Out of 30 cases of papillary carcinoma, four were papillary 
microcarcinomas with sizes ranging from 0.4 to 1.0 cms. Cystic lesion with 
papillary structures along the cyst wall was found in six cases. Stromal bone 
formation was noted in one. Encapsulation was found in one of the cases. The 
tumor was multifocal in ten patients (33.3%) and two patients had lymph node 
involvement. Extrathyroidal extension beyond the thyroid capsule was found in 
three of the patients with papillary carcinoma, of which one patient had lymph 
node involvement in addition. 
               Amongst the follicular neoplasms of thyroid, all the lesions showed a 
thick fibrous capsule enclosing the nodule, with a thin rim of normal thyroid 
parenchyma around. One of the cases had  a thin capsule. Cervical lymph node 
involvement was found in both the cases of medullary carcinoma and with 
necrosis in one. The lone case of anaplastic carcinoma in our study was 11.5 
cms in size involving the right lobe and isthumus with extrathyroidal extension 
into the superior mediastinum. The tumor was found to be displacing the 
trachea with compression and also encasing the right common carotid artery by 
CT neck. The cut surface revealed areas of necrosis and hemorrhage. Bilateral 
cervical and mediastinal lymph nodes were also involved by the tumor.  
THYROID NEOPLASMS- ANALYSIS OF MICROSCOPIC FEATURES:                
               Hematoxyllin and eosin stained sections were analysed for the 
following: architectural pattern, nuclear atypia, vascular invasion, capsular 
invasion, stromal sclerosis, mitoses, necrosis, associated chronic thyroiditis and 
coexisting other neoplasms. Apart from these, presence of amyloid deposits and 
squamous metaplasia were also studied in medullary carcinoma. 
               29 0f the the 30 cases of papillary carcinoma showed obvious papillary 
architecture (Fig. 1, 2), one of which showed in addition oncocytic cells (Fig. 
3). One case which did not show papillary architecture showed a follicular 
architecture and was lined by cells with nucler features typical of a papilary 
carcinoma [encapsulated follicular variant (Fig. 5)].  Solid areas were noted in 
 foci in two of the cases. Four cases in our study were of micropapilary 
carcinoma (Fig. 4) and were discovered incidentally.. Mild nuclear atypia and 
focal capsular invasion was noted (Fig. 6) in four of the cases. Table VIII and 
chart II depict the various patterns of papillary carcinoma reported in our study. 
TABLE VIII: Histological distribution of papillary carcinoma thyroid: 
Papillary Carcinoma No of cases Incidence (%) 
Usual type 23 77% 
Micro carcinoma variant 6 20% 
Encapsulated Follicular variant 1 3% 
 
CHART II: Incidence of classical type and variants of papillary carcinoma 
thyroid: 
 
               Two cases had cervical lymph node involvement at the time of 
diagnosis (Fig. 7). Stromal sclerosis was noted in sixteen of the cases with 
stromal bone formation in one (Fig. 8). Other thyroid lesions were found to 
coexist in 10 of the 30 cases. They are chronic thyroiditis seen in 30% cases 
(Fig 9), follicular adenoma (7%) and follicular neoplasm of uncertain malignant 
potential (3%).   
TABLE IX: Histological distribution of follicular neoplasm: 
Type of neoplasm No of cases 
Follicular 
adenoma 
Usual type 12 
Micro follicular adenoma- signet ring cell type 1 
Hurthle cell adenoma 1 





Minimally invasive follicular carcinoma 2 
               
               Among the 17 cases of follicular neoplasms, 15 cases were benign 
(folicular adenoma) and 2 were malignant. Of the 15 benign neoplasms, 12 were 
of  usual type with a thick fibrous capsule (Fig. 12, 13) and 3 were variants 
which are microfollicular adenoma of signet ring cell type (Fig. 14, 15), hurthle 
cell adenoma (Fig. 16, 17) and a follicular neoplasm of uncertain malignant 
 potential (Fig. 18). Both the cases of follicular carcinoma showed minimal focal 
capsular invasion (Fig. 19). Table IX gives the details of follicular neoplasm 
and its variants. 
               In both the cases of medullary carcinoma, the cells were arranged 
predominantly in nests and sheets  (Fig. 21, 22) with mitotic figures of about 2/ 
25 high power fields in both of the cases. Both the cases of medullary 
carcinoma showed the presence of acellular amorphous eosinophilic deposits of 
amyloid in the stroma (Fig. 23). Presence of amyloid in the sections were 
confirmed using congo red stain (Fig. 24). Under polarised microscopy, apple 
green birefringence was observed  (Fig. 25). Invasion of the thyroid capsule 
with capsular blood vessel invasion (Fig. 26) was noted in one and the other 
showed tumor at the surgical resection margins. Bilateral upper and deep 
cervical lymph node involvement was found in both the cases at the time of 
diagnosis (Fig. 27). 
              Anaplastic carcinoma exhibits prodominantly solid pattern of growth 
with marked nuclear pleomorphism, necrosis and increased mitoses of about 14 
/ 25 high power fields (Fig. 29, 30). A transition from follicular carcinoma was 
observed in foci (Fig. 31, 32). Invasion into the adjacent skeletal muscle 
bundles were also seen. 
 
 THYROID NEOPLASMS- ANALYSIS OF STAGE OF THE TUMOR:                
              Staging was done according to the TNM classification and staging of 
thyroid carcinomas, considering the age, size, lymph node involvement, extra 
thyroidal extension, type of neoplasm and presence or absence of metastases. 
Table X and chart III depict the distribution of thyroid neoplasms based on their 
stage at diagnosis. 80% 0f papillary carcinoma presented in stage I and II, which 
has a good prognosis. The remainder was in stage III. Stage IV was not 
observed in our study. Both cases of medullary carcinoma were in stage IV A 
and the anaplastic carcinoma was in stage IV B. as of now, there is no stage 
grouping described for minimally invasive follicular carcinoma. Hence it is not 
represented in the table. 









I 14 0 0 
II 10 0 0 
III 6 0 0 
Iva 0 2 0 
IVb 0 0 1 




THYROID NEOPLASMS- IMMUNOHISTOCHEMICAL ANALYSIS OF 
EXPRESSION OF CD15 ANTIGEN:                
               Sections of thyroid neoplasms stained with CD 15 antibody were 
studied for the intensity of staining and percentage positivity of the tumor cells 
(scoring). The intensity of stainging were graded as mild, moderate and strong. 
Scoring was done by counting 500 cells in the well stained areas of high tumor 
load and a percentage of positivity was calculated accordingly. Areas with 
nonspecific staining if any, and hemorrhage are excluded, as blood cells like 
neutrophils and macrophages would also show CD 15 immuno marker 
expression. 
                 Twelve of the 50 thyroid neoplasms of the study showed positivity for 
CD 15. Thus the incidence of CD15 expression in thyroid neoplasm in our study 
was 24%. Papillary carcinomas accounted for 66% of the overall positivity. 
Table XI details the incidence of CD15 expression in the various histological 
types of thyroid neoplasms. 
TABLE XI: Incidence of CD15 expression in various types of thyroid 
neoplasms. 
Type of neoplasm 
Total No of 
cases 
No of cases 
positive for CD15 
Percentage 
positivity 
Papillary carcinoma 30 8 26.7% 
Follicular adenoma 15 2 13.3% 
Medullary carcinoma 2 2 100% 
Miscellaneous 3 0 0% 
Total 50 12 24% 
 
               Of the 30 papillary carcinomas, 8 were CD15 positive (26.7%). Seven 
of the 8 cases showed focal membranous staining (Fig 10, 11), one of which 
also showed focal cytoplasmic dot like reactivity. One case showed diffuse 
membranous staining  (moderate to strong).  The staining score  ranged from 
26% to 100%.  
              Both the medullary carcinomas encountered in this study showed a 
Strong cytoplasmic dot like staining (Fig. 28) with 63% and 96% positivity. The 
lone anaplastic carcinoma seen in our study was negative for CD15 marker 
expression. CD15 expression was also seen in 2 of the 15 cases of benign 
folicular neoplasms, both of which showed focal cytoplasmic dot like staining 
(Fig. 20) and was about 53% and 67%. 
TABLE XII: Incidence of CD15 expression in papillary carcinoma across 
various stages: 
Stage Total no of cases No of cases positive for CD15 Incidence (%)
I 14 2 14.3% 
II 10 3 30% 
III 6 3 50% 
IV - - - 
Total 30 8 27% 
 
               In cases of papillary carcinoma, CD15 immuno marker expression was 
more in patients with stage III and stage II disease and in the age groups of 45 
and above (Table XII, XIII). CD 15 expression was very high in males. The 
scoring showed a general tendency for increased expression with increasing 
stage of the tumor. It was also found that, patients with capsular blood vessel 
 invasion, extra thyroidal extension, lymph node metastases had a high degree of 
marker expression in the tumor cells (> 50%). No generalizations could be 
drawn with regard to hormone status and CD15 expressivity as almost all of the 
cases were euthyroid. 











1 70 / M II 100% Euthyroid 
Capsular blood vessel 
invasion 
2 50 / M III 72% Euthyroid 
Extra thyroidal 
extension 
3 45 / F III 61% NA 
Extra thyroidal 
extension, lymph node 
metastasis (4/13) 
4 45 / F II 58% Euthyroid _ 
5 46 / F III 41% Euthyroid Multifocal 
6 32 / F I 28% Euthyroid _ 
7 41 /F I 27% Euthyroid 
Multifocal, Stromal 
bone formation 
8 27 / F II 26% Euthyroid _ 
 TABLE XIV:   Characteristics of medullary carcinoma thyroid which are 
positive for CD15: 






67 /M IV A 96% Hypothyroid 
Necrosis + 
Calcitonin high 
38 / M IV A 63% Euthyroid 
Necrosis – 
Calcitonin high 
             
              Table XIV shows that both the cases of medullary carcinoma of thyroid 
which were positive for CD15 showed >50% expression and had a similar 
advanced stage at presentation (Stage IV A). 
              Two of the 15 cases of follicular adenomas which showed positivity for 
CD 15 also showed >50% expression (Table XIV).  Peculiarly both these cases 
showed a common unique histological finding i.e., focal clearing of nuclei and 
occasional nuclear grooves.  
TABLE XV:  Characteristics of follicular adenoma thyroid which are positive 
for CD15: 
Age / Sex CD15 expression Hormone status Additional features 
48 / M 67% NA Focal clearing of nuclei 
and nuclear grooves 




Fig 1: Papillary carcinoma. Complex arborising       Fig 2: Typical nuclear features of Papillary  





    
Fig 3: Papillae covered by oncocytic cells with        Fig 4:  A focus of micropapillary carcinoma  
with eosinophilic cytoplasm. H & E (40x)                surrounding normal thyroid tissue.  H & E (10x) 






       
 
Fig 5: Encapsulated follicular variant of Papillary      Fig 6: Papillary carcinoma with focal invasion  
carcinoma showing a thin capsule and neoplastic      into the capsule. H & E (10x).                                                          
cells in follicular pattern. H & E (10x) 
 
 
     
Fig 7: Lymph node showing metastatic foci of         Fig 8: Extensive stromal sclerosis with bone  







    
Fig 9: Lymphoid aggregates infiltrate the follicles.  Fig 10: Papillary carcinoma showing diffuse  
A few lamellated psammoma bodies are present.    strong membranous positivity for CD 15. IHC  
H & E (10x).                                                              with hematoxylin counter stain (10x) 
 
                                              
 
    
Fig 11: Diffuse strong membranous positivity of      Fig 12: Follicular adenoma with a thick capsule  
CD 15 in Papillary carcinoma. IHC with                   and neoplastic cells in follicular pattern. H & E   





    
Fig 13: Encapsulation and neoplastic follicles of     Fig 14: Collection of large vacuolated cells with  
variable sizes in Follicular adenoma H & E (40x).  eccentric nuclei and microfollicles in micro  
                                                                                   follicular adenoma- signet ring cell type. H &E  
                                                                                                  
  
 
    
Fig 15: Signet ring like cells in Micro follicular              Fig 16: Hurthle cell neoplasm with a fibrous  






      
Fig 17: The follicles in Hurthle cell neoplasm lined   Fig 18: uncertain capsular invasion in a follicular  
by cuboidal cells with eosinophilic granular                neoplasm- Follicular neoplasm of uncertain  
cytoplasm. H & E (40x)                                               malignant potential. H & E (10x) 
 
 
    
Fig 19: Follicular neoplasm with a small foci of       Fig 20: Follicular neoplasm showing strong dot 
limited capsular invasion. H & E (40x)                     like cytoplasmic positivity for CD 15 in more      
                                                                                   than 50% of the tumor cells,  IHC with  





    
Fig 21: Medullary carcinoma showing  nests and    Fig 22: Nests of tumor cells with pale cytoplasm  
islands of tumor cells separated by fibrous stroma.  and round nuclei with stippled chromatin. H & E  




    
Fig 23: Medullary carcinoma showing nests of     Fig 24: The acellular deposits separating the cell 
tumor ells. Homogenous pink acellular deposits   nests are congophillic. Congo red (40x) 
are seen in the stroma (arrow). H & E (10x) 





              
Fig 25:  Medullary carcinoma Apple green               Fig 26: A blood vessel shows tumor cells of              
birefringence of Amyloid  deposits in polarizing      medullary carcinoma adherent to the endothelial     




     
Fig 27: Medullary carcinoma replacing the lymph Fig 28: Medullary carcinoma shows strong granular  
node. Lymphoid tissue with the subcapsular sinus     cytoplasmic staining in most of the tumor cells.  
is  at the lower border of the field. H & E (10x)        IHC with hematoxylin counter stain -CD 15 (40x) 





    
 Fig 29:  Follicular carcinoma with cells in solid      Fig 30. High magnifiction shows mild nuclear  




    
Fig 31: Anaplastic carcinoma shows large               Fig 32. High magnifiction shows few bizarre cells  
pleomorphic cells in solid sheets. H & E (10x)         multilobate nuclei. Increased mitotes with                                        
















               Thyroid neoplasms are on the rise and pose a significant challenge to 
both pathologists and therapists. With increasing discoveries of variants of each 
type of malignancy (for eg: Follicular variant of papillary carcinoma, follicular 
carcinoma with minimal capsular invasion etc), it poses diagnostic challenge to 
the routine pathologists. Therapy too is confounded by the fact that the variants 
of these malignancies differ significantly in their clinical behaviour. There is a 
lot of research in progress to identify prognostic indicators which could solve 
the clinicians’ dilemma. One of the molecules being studied is CD15, a blood 
group antigen. Hence this study was done to look at the possibility of using 
CD15 as a prognostic marker in various thyroid neoplasms. 
               50 cases of thyroid neoplasms diagnosed between Jan 2006 to Sep 
2009 at PSG Institute of Medical Sciences and Research, were analyzed for 
CD15 immuno marker expression. Thyroid neoplasms constituted about 2.16% 
of overall neoplasms reported during the study period. A large study by Rosai J 
et al showed that thyroid neoplasms accounted for 1% of the overall neoplasms 
and is a rare cause of death [10]. The increased incidence in our study could be 
due to the fact that the western part of Tamilnadu (a state in south India) which 
includes Nilgiris district, an endemic zone for goiter. 
               Out of 50 cases of thyroid neoplasms, 30 were papillary carcinomas, 
15 were follicular adenomas, two cases each of medullary carcinoma and 
 minimally invasive follicular carcinoma and a case each of anaplastic carcinoma 
and follicular neoplasm of uncertain malignant potential.  
              Papillary carcinomas accounted for 86% of the thyroid malignancies. 
This incidence is significantly higher compared to western literature [46, 47] (60- 
80%) and also from that reported in a study from North India [10] (64%). The 
wide age distribution and female preponderance observed was consistent with 
literature.  
              The incidence of medullary carcinoma was 5.7% which is quite similar 
to the incidence observed by Rosai et al [10]. The incidence of other thyroid 
malignancies such as anaplastic carcinoma and minimally invasive follicular 
carcinoma was quite low as is observed in most studies. Most of the thyroid 
neoplasms were euthyroid and only 12% of the tumors showed hormonal 
variations. This is consistent with the observations made by several studies in 
the literature [46, 47]. 
              78% of the thyroid neoplasms were < 4 cm in size. PSG Institute of 
Medical Sciences and Research is a tertiary care hospital and has advanced 
diagnostic facilities such as Ultrasound guided fine needle aspiration and 
Radionuclide scanning, which could have resulted in the early detection of 
thyroid neoplasms. 
              The microscopy of papillary carcinoma was of the usual type in 25 of 
the 30 cases while 4 were of microcarcinoma. All the 4 of the latter were less 
than 1 cm and were unencapsulated as is described in the literature [2, 46]. 
Predictably, all the 4 were incidental. 3 of them were found along with 
predominant areas of nodular colloid goiter and 1 was found to coexist with 
Hashimoto thyroiditis. 
              12 of the 15 follicular adenomas were of the classical type. Of the 3 
variants, encountered in our study, Signet ring cell follicular adenoma posed a 
diagnostic challenge as metastatic deposits had to be ruled out. After extensive 
clinical investigation (Endoscopy, Ultrasound etc) it was labeled so. The mucin 
in the signet ring like cells was found to be Alcian blue positive (Fig 15) as is 
described in Fletchers textbook of ‘Diagnostic histopathology of tumors’ [9]. The 
histology of medullary carcinoma and anaplastic carcinoma showed no 
significant variations from those described in the literature. 
              72% of all the thyroid cancers seen in our study were either in stage I 
or II. This correlates with the increased incidence of small sized tumors and of 
papillary carcinoma in our study, apart from a female preponderance. Both the 
cases of medullary carcinoma were in advanced stage (IV A) which correlates 
with the observation of  Boostrom SY et al in their article published, where they 
compared the staging criteria of 1997 and 2002 [48]. They argue that medullary 
 carcinoma may be restaged to III for tumors with N0 status. However in our 
study there was no such dilemma as both the cases showed nodal involvement. 
              The focus of this study was to observe the incidence of CD15 
expression in thyroid neoplasms as it is predicted to be a prognostic marker. CD 
15 expression was analyzed in various thyroid neoplasms and the results are 
depicted in Table XI. Literature on CD15 expression from several studies states 
that these blood group antigens were not expressed in the normal thyroid tissue 
and that they get progressively expressed strongly in stage III papillary 
carcinomas and in more aggressive neoplasms. This could possibly be 
secondary to oncogenic transformation and subsequent increased production of 
Lacto-N-fucopentaose III ceramide.  
              As seen in Table XII and XIII, 50% of the stage III papillary carcinoma 
was positive for CD15 and the expression of the marker ranged from 41% to 
72%. Miettinen et al and Schroder et al also observed that CD15 expression 
increases with increasing stage of papillary carcinoma, thus accounting for a 
poor prognosis. Both the cases of papillary carcinoma where we observed 
extrathyroidal extension showed strong CD15 positivity in more than 50% of 
the tumor cells. The lone case of papillary carcinoma with capsular blood vessel 
invasion was also positive for CD15. Thus CD15 expression was found to be 
high in tumors showing features which are generally indicative of a poor 
prognosis. 
             Both the cases of medullary carcinoma which were in stage IV showed 
high percentage of CD15 expression. This correlates with the Neuholds 
observation in his article published [44]. Of the 2 cases of medullary carcinoma, 
one showed tumor necrosis and in this case there was a very high expression 
(96%) of CD15. A large series of studies may be required to see the incidence 
of CD15 in tumors with necrosis. The lone case of anaplastic carcinoma and 2 
cases of minimally invasive follicular carcinoma were negative for CD15. There 
is not much literature on the expression of CD15 in these cancers owing to their 
very low incidence. 
            From our study, we infer that CD15 expression was strongly expressed 
in papillary carcinoma of advanced stage and with poor prognostic factors like 
extrathyroidal extension. A similar expression was also seen in medullary 
carcinoma. Two of the cases of follicular adenoma with a focus of cells showing 
nuclear features of papillary carcinoma showed CD15 expression which might 

















  SUMMARY  
 SUMMARY 
1. Thyroid neoplasms accounted for 2.16% of the total neoplasms during 
the study period (3 years and 9 months). 
2. Benign tumors comprised only 31% of the thyroid neoplasms, all of 
which were follicular adenomas, 
3. 93% of the malignant thyroid neoplasms were of papillary carcinoma 
type. 
4. Of the study group (50 cases), 15 were follicular adenoma and 35 
were malignancies of which papillary carcinoma accounted for 86%. 
5. CD 15 was positive in only 12 0f the 50 cases of the study group 
(24%). 
6. 8 of the 12 CD 15 positive cases were papillary carcinoma. 2 follicular 
adenomas were also positive. 
7. The expression of CD 15 was more common in tumors in stage III or 
IV and hence can be used as a prognostic marker. 
8. All the malignancies (irrespective of the histologic type) which had 

















              CD 15 immunohistochemical marker is being studied as a prognostic 
marker for thyroid malignancies. Though only 24% of the thyroid neoplasms 
showed expression of CD15 in our study group, it was found to be positive in 
all those malignancies presenting at a higher clinical stage and also with poor 
prognostic indicators such as blood vessel invasion. Our study also brought out 
a considerable percentage of expression of CD15 in two cases of follicular 
adenoma, where a focus showed typical nuclear features of papillary carcinoma 
explaining the possibility of missing a papillary focus in an otherwise follicular 
adenoma. Though from our study, it is proved that CD15 can be used for 
prognostication and diagnosis of thyroid malignancies; a larger prospective 
study recruiting more number of cases is essential to prove the utility of CD 15 
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Diagnosis Stage IHC % Misc 
1 150/06 30/M 2.6cm Euthyroid 
Minimally invasive 
follicular carcinoma
- - - 






3 747/06 49/F 3.5cm Euthyroid Papillary carcinoma II - 
Multifocal, 
cystic 
4 888/06 50/F NA Euthyroid Papillary carcinoma III - 
Extrathyroid
al extension 
5 1253/06 51/F 0.5cm Hyperthyroid
Papillary 
microcarcinoma 
I - Multifocal 
6 1562/06 32/F 2.3cm Euthyroid Follicular adenoma - - - 
7 1801/06 38/M 1.8cm Euthyroid 
Medullary 
carcinoma 
IV A + - 
8 1906/06 48/M 4.2cm NA Follicular adenoma - + - 
9 2093/06 23/F 5.5cm Euthyroid Papillary carcinoma III - - 
10 2110/06 43/M 2.5cm Euthyroid Follicular adenoma - - - 
11 2230/06 57/M 3.0cm Euthyroid FN- UMP - - - 
 
 12 2232/06 58/M 7.0cm Euthyroid 
Microfollicular 
adenoma- signet 
ring cell type 
- - - 
13 2780/06 52/F 
0.4- 
2.3cm 
Euthyroid Papillary carcinoma II - Multifocal 
14 2838/06 35/F 9.5cm Euthyroid Follicular adenoma - - - 
15 3173/06 34/F 3.0cm Euthyroid Follicular adenoma - - - 
16 29/07 51/F 3cm Euthyroid Papillary carcinoma II - Cystic 
17 220/07 70/M 
2.0- 
4.0cm 
Euthyroid Papillary carcinoma II + Multifocal 
18 307/07 38/M 0.5cm Euthyroid 
Papillary 
microcarcinoma 
I - - 
19 600/07 67/M 5.5cm Hypothyroid 
Medullary 
carcinoma 
IV A + - 
20 1310/07 43/F 3.3cm Euthyroid Follicular adenoma - - - 
21 1560/07 50/F 
0.3- 
1.0cm 
Euthyroid Papillary carcinoma I - Multifocal 
22 1572/07 30/F 0.4cm Euthyroid 
Papillary 
microcarcinoma 
I - - 
23 1651/07 36/F 5.5cm Euthyroid Follicular adenoma - - - 
24 2118/07 45/F 2.5cm Euthyroid Follicular adenoma - - - 
 25 2710/07 34/F 3.0cm Euthyroid Follicular adenoma - - - 
26 2874/07 65/F 1.3cm Hypothyroid Papillary carcinoma I - - 
27 3335/07 45/F 6.0cm Euthyroid 
Hurthle cell 
adenoma 
- - - 
28 3478/07 35/F 4.5cm Hyperthyroid Follicular adenoma - + - 
29 3679/07 27/F 3.0cm Euthyroid Papillary carcinoma II + - 
30 3693/07 46/F 
0.8- 
5.0cm 
Euthyroid Papillary carcinoma III + Multifocal 
31 648/08 55/F 1.0cm Euthyroid Follicular adenoma - - - 
32 1101/08 30/F 3.0cm Hypothyroid 
Minimally invasive 
follicular carcinoma
- - - 
33 1376/08 24/F 5.5cm Euthyroid Papillary carcinoma III - Cystic 
34 1422/08 53/M 2.0cm Euthyroid Papillary carcinoma I + - 
35 1837/08 30/F 0.3cm Euthyroid 
Encapsulated 
follicular variant of 
Papillary carcinoma
I - - 
36 1865/08 29/M 2.5cm Euthyroid Papillary carcinoma II - - 
37 2062/08 35/F 4.0cm Euthyroid Follicular adenoma - - - 
38 2222/08 27/F 2.4cm Euthyroid Papillary carcinoma II - - 
39 2850/08 25/M 0.5cm Euthyroid 
Papillary 
microcarcinoma 
I - - 
 40 3187/08 27/F 0.5cm Hyperthyroid
Papillary 
microcarcinoma 
I - - 
41 4248/08 32/F 1.5cm Euthyroid Papillary carcinoma I + - 
42 11/09 45/F 3.5cm Euthyroid Papillary carcinoma II + - 
43 229/09 28/F 
0.3, 
1.4cm 
Euthyroid Papillary carcinoma I - 
Multifocal, 
cystic 
44 824/09 41/F 
0.3-
0.8cm 





45 915/09 50/M 2.0cm Euthyroid Papillary carcinoma III + 
Extrathyroid
al extension 
46 920/09 59/M 
1.0-
3.0cm 
Euthyroid Papillary carcinoma II - Multifocal 
47 1218/09 32/F 1cm Euthyroid Papillary carcinoma I - Cystic 




















 CD15 IHC STAINING PATTERN IN POSITIVE CASES 
PAPILLARY CARCINOMA- IHC 
S.No HP. No AGE SEX SIZE DIAGNOSIS STAGE TYPE & INTENSITY 
PERCEN
TAGE 






















































cytoplasmic dot like 
27% 










 MEDULLARY CARCINOMA- IHC 
 
S.No HP. No AGE SEX SIZE DIAGNOSIS STAGE TYPE & INTENSITY 
PERCEN
TAGE 




Diffuse strong cytoplasmic 
dot like 
96% 









Follicular adenoma- IHC 
 
S.No HP. No AGE SEX SIZE DIAGNOSIS STAGE TYPE & INTENSITY 
PERCEN
TAGE 




Focal Moderately strong 
cytoplasmic dot like 
67% 




Focal strong cytoplasmic 
dot like and membranous 
53% 
 
 
